Cleveland BioLabs receives patent for radiation protection drug
The U.S. Patent and Trademark Office has issued Cleveland BioLabs a patent titled "Modulating Apoptosis" covering the method of protecting humans from radiation using flagellin or its derivatives, including CBLB502.
This patent was already granted by the nine member countries of the Eurasian Patent Organization, and two additional countries, according to the company.
CBLB502 is being developed under the FDA’s animal efficacy rule to treat acute radiation syndrome or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon or from a nuclear accident and as a supportive care measure to reduce and prevent occurrence of side effects of radiotherapy or chemotherapy in cancer treatment, said Cleveland BioLabs.
The Buffalo, N.Y.-based company has also filed two additional new patent applications related to protectan technology in the U.S. around CBLB502 and related protectan compounds, including new methods of use of flagellin derivatives and screening for new compounds with similar properties.
This patent was already granted by the nine member countries of the Eurasian Patent Organization, and two additional countries, according to the company.
CBLB502 is being developed under the FDA’s animal efficacy rule to treat acute radiation syndrome or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon or from a nuclear accident and as a supportive care measure to reduce and prevent occurrence of side effects of radiotherapy or chemotherapy in cancer treatment, said Cleveland BioLabs.
The Buffalo, N.Y.-based company has also filed two additional new patent applications related to protectan technology in the U.S. around CBLB502 and related protectan compounds, including new methods of use of flagellin derivatives and screening for new compounds with similar properties.